Alcohol consumption has been declared a Group 1 carcinogen by the International Agency for Research on Cancer (IARC) and is a potential risk factor for several types of cancer mortality. However, evidence for an association with prostate cancer survival remains inconsistent. We examined how alcohol consumption post-diagnosis was associated with survival after prostate cancer diagnosis. Men diagnosed with prostate cancer (n 5 829) in Alberta, Canada between the years 1997 and 2000 were recruited into a population-based case-control study and then followed for up to 19 years for survival outcomes. Pre-and post-diagnosis alcohol consumption, clinical characteristics and lifestyle factors were collected through in-person interviews shortly after diagnosis and again 2-3 years post-diagnosis. Cox proportional hazards were used to examine how post-diagnosis alcohol consumption was associated with all-cause and prostate cancer-specific mortality (competing risk analysis too), in addition to first recurrence/ progression or new primary cancer. Most participants reported drinking alcohol (once a month for 6 months) post-diagnosis (n 5 589, 71.0%). Exceeding Canadian Cancer Society (CCS) alcohol consumption recommendations (2 drinks/day) postdiagnosis was associated with prostate cancer-specific mortality relative to non-drinkers (aHR: 1.82, 95% CI: 1.07-3.10) with borderline evidence of a linear trend. Interestingly, those in the highest quartile of drinks/week pre-and post-diagnosis also had a twofold increase for prostate-specific mortality (aHR: 2.67, 95% CI: 1.28-5.56) while controlling for competing risks. Our results support post-diagnosis alcohol consumption was associated with increased mortality after prostate cancer diagnosis, specifically for prostate cancer-related death. Future studies focused on confirming this burden of disease are warranted.
Introduction
Alcohol consumption has become a large part of many cultures and social norms worldwide. Excessive alcohol consumption is a major health concern, more common in men 1 and an estimated 80% of Canadians (22 million) consume alcohol and of those, 3.1 million Canadians drink enough alcohol to be at risk of injury and harm. 2 In addition, alcohol is attributable to an increased risk of several health problems including but not limited to: heart disease, liver disease, sleep disorders, depression, stroke and several types of cancer, birth defects, injuries (caused by risky behaviors) and alcohol use disorders. 3, 4 Specifically, alcohol has been declared a Group 1 carcinogen by the International Agency on Cancer Research (IARC) with no safe limit regarding cancer risk. 5 While alcohol consumption has been identified as a risk factor for several types of cancer, 6 with respect to cancer survival, the relationship between alcohol consumption and risk of mortality is less clear and still under debate. The inconsistencies between epidemiologic studies are a large contributing factor, in addition to the evidence of a protective association found with all-cause mortality or other health outcomes such as cardiovascular disease. 7, 8 Furthermore, some evidence suggests that heavy drinkers have an elevated risk but not light-to-moderate drinkers. 9 Therefore, low risk guidelines have been developed by the Canadian Cancer Society (CCS), recommending less than two alcoholic beverages/ day for men and less than one/day for women. 10 Prostate cancer is the most common cancer in men, responsible for 20.7% of diagnoses and 9.6% of cancerrelated mortality in 2017. 11 To date factors influencing prostate cancer incidence and survival after diagnosis are poorly understood. Recently a meta-analysis has shown that alcohol consumption increases prostate cancer incidence, 12 however, few studies have examined the effects of alcohol consumption on survival [13] [14] [15] and only one study has examined progression of prostate cancer and how alcohol metabolites are related. 16 Therefore, more research regarding the role of alcohol consumption in prostate cancer survival is needed. We previously examined the role of lifetime alcohol consumption on prostate cancer risk in a population-based case-control study and found alcohol consumption to significantly increase the risk of prostate cancer. 17 Our objective here was to examine how alcohol consumption was related to survival in men diagnosed with prostate cancer. Specifically, we examined all-cause mortality, prostate cancer-specific mortality and first recurrence/progression or new primary cancer. Second, our objective was to identify if different patterns of alcohol consumption behavior over the life-course exist in this cohort of prostate cancer survivors.
Materials and Methods

Study population
Newly diagnosed men with prostate cancer (n 5 987) between the years 1997 and 2000 were recruited to a population-based case-control study and 830 were reconsented to a prospective cohort study between 2000 
Data collection
In the case-control study data collection, 17 participants were asked to recall their lifetime alcohol consumption habits in an interview using cognitive methods and a recall calendar. This interview included questions regarding all types of alcohol (beer, liquor and wine) starting from childhood to their current alcohol consumption levels. In addition, participants were able to report changes in drinking habits over their lifetime, if appropriate. Other lifestyle and medical data were also collected from participants at the time of the interview. Specifically comorbidities were collected to represent postdiagnosis comorbidities extracted from medical records after diagnosis. After diagnosis, participants in the prospective cohort study were asked to recall their alcohol consumption habits between diagnosis and 2-3 years post-diagnosis during an in-person interview using the same questionnaire on alcohol intake as was used in the case-control study. Therefore, we have alcohol consumption data continuously measured throughout the life-course. Participants were labeled as nondrinkers if they did not consume alcohol in the time period of data collection and therefore, abstained from alcohol consumption. Medical chart abstractions were completed by health record technicians from the Alberta Cancer Registry. They recorded data on treatments, first recurrence/progression or new primary cancer and whether the death was prostate cancer related or not. All-cause mortality was continually updated by the Department of Cancer Surveillance and Reporting of Alberta Health Services. The last update on cancer outcomes was completed on January 20, 2017, with up to 19 years of follow-up for the aforementioned outcomes.
Statistical analysis
Descriptive representation of all the post-diagnosis alcohol consumption, lifestyle and clinical data were estimated and are presented here. Alcohol consumption variables (tested for
What's new? Drinking alcohol can increase the risk of developing cancer. But after diagnosis, what does it do? Here, the authors looked for a correlation between alcohol consumption and mortality after prostate cancer diagnosis. They interviewed prostate cancer patients immediately after diagnosis and again 2-3 years later, to record their alcohol habits before and after cancer, disease characteristics, and other lifestyle factors. Mortality data were collected for up to 19 years. Compared with non-drinkers, they found, men who imbibed more than 8 drinks weekly had higher mortality, and those in the highest quartile of alcohol consumption showed the biggest effect.
linearity using the Martingale residuals 20 ) were categorized based on CCS alcohol recommendations and categorized into quartiles based on the total drinks/week consumed up to 3 years post-diagnosis. To assess the change in alcohol consumption from pre-to post-diagnosis, quartile cut-points of lifetime drinks/week and post-diagnosis drinks/week were tabulated and categorized into five different behavior groups. These groups included: (1) no drinking (pre) to no drinking/ low (post), (2) low (pre) to no drinking/low (post), (3) no drinking/low (pre) to high (post), (4) high (pre) to no drinking/low (post), or (5) high to high (both pre-and post-diagnosis). The first group, no drinking pre-diagnosis to no drinking/low drinking post-diagnosis, served as the referent group. See Supporting Information Table S1 for details on the group definitions.
When examining the associations between alcohol consumption (up to 3 years post-diagnosis) and all-cause mortality, prostate-specific mortality and first recurrence/progression or new primary cancer; Cox proportional hazard models were fit and the proportional hazards were assessed utilizing the Schoenfeld residuals test. 21 Cox proportional hazards were fit to produce fully adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) and the method of Fine and Gray was used in a competing risks approach for prostate-specific mortality. A priori, models were adjusted for the following variables: age at diagnosis (in years), stages (T2, T3/T4), prostatectomy (yes/no), initial hormone therapy treatment (yes/no), initial radiation therapy treatment (yes/no), prostate specific antigen (PSA) levels at diagnosis (<4, 4 to <10, 10 to <20, 201), and post-diagnosis Charlson comorbidity index score (measured). The same aforementioned variables were assessed for effect modification using likelihood ratio tests. In addition, confounding of the associations between alcohol consumption and survival outcomes was assessed for the following variables: total lifetime physical activity (Metabolic equivalent (MET)-hours/ week/year), body mass index (BMI) at diagnosis (kg/m 2 ), average daily caloric intake (kcal/day), education level (<high school, high school diploma, trade certificate, other nonuniversity degree, university degree), smoking status at diagnosis (never, former, current), family history of cancer (yes/no), region of residence (urban, rural), Gleason score at diagnosis (<7, 7) and how often (on average) participants went for a general check-up in their lifetime prior to diagnosis of prostate cancer. These analyses were reported on total average alcohol consumption as the primary analyses. Exploratory analyses on individual types of alcohol (beer, liquor and wine) were also presented.
To examine the robustness of the final survival models presented here, several sensitivity analyses were performed. First, to determine if reverse causation influenced the results, we removed the first 2 years of follow-up time from all participants on the post-diagnosis (up to 3 years) alcohol consumption models. Next, Fine and Gray competing risk methods 22 producing subdistribution hazard ratios were used as a sensitivity analysis in the prostate cancer-specific mortality analyses to determine if death from other causes (not prostate cancerrelated) influenced the results. Furthermore, the analyses were repeated while removing stages T3/T4 participants to determine if disease severity had an influence on the results. Models were also run with a non-drinker referent group in addition to a referent group with the lowest level of alcohol consumption to increase interpretability and generalizability to a broader population.
A secondary analysis was performed to determine if there were different clusters of alcohol patterns over the life-course using group-based trajectory modeling (GBTM). 23 This method uses finite mixture modeling to approximate unknown distributions of trajectories within a dataset. When using GBTM methods (Traj for Stata V R ), the Bayesian information criterion (BIC) was used to assess model fit (number of groups and functional form) in addition to, non-overlapping confidence intervals (i.e., distinct and individual trajectories), posterior probabilities 0.7 and a substantial number of participants within each group. 24 For the purposes of this analysis, we fit up to five groups with either a linear or quadratic functional form of total alcohol consumption (number of drinks per each 10-year period). Therefore, participants could have up to eight different patterns from childhood drinking to current drinking habits prediagnosis (based on decades of alcohol consumption).
All statistical analyses were performed in Stata v.13 (StataCorp LP, College Station, TX) with an a < 0.05.
Results
Out of the 829 men analyzed, 528 men died from any cause, 185 died from their prostate cancer and 379 experienced a first recurrence/progression or new primary cancer between 2000 and 2017 (see Fig. 1 for full details of prospective cohort follow-up). Furthermore, these men were on average 67.3 years of age and mostly stage T2 at diagnosis. 17, 19 The majority of participants reported drinking alcohol (once a month for 6 months or more) in their lifetime (n 5 909, 92.1%). There were at total of 240 non-drinkers post-diagnosis (Table 1) . Furthermore, when comparing descriptive characteristics between post-diagnosis average alcohol consumption quartiles, it appeared that men in the highest alcohol consumption quartile were most likely to be current or former smokers, had lower physical activity levels and more likely to live in an urban area, respectively.
When examining effect modification in the post-diagnosis alcohol consumption exposures with respect to all-cause mortality, prostate cancer-specific mortality and first recurrence/ progression or new primary cancer outcomes, none of the interactions produced evidence of effect modification. In all of the following analyses, the proportional hazards (Schoenfeld residuals test) and alcohol consumption linearity (Martingale residuals test) assumptions were met.
Associations between post-diagnosis (up to 3 years) alcohol consumption and cancer outcomes are presented in Table 2 (mortality outcomes) and Supporting Information Table S2 (first recurrence/progression or new primary cancer). With respect to all-cause mortality, we observed a suggestive (albeit not statistically significant in most instances) protective association of increased alcohol consumption for allcause mortality. Participants with the CCS recommended <2 drinks/day of alcohol intake post-diagnosis were associated with a reduced risk of all-cause mortality relative to non-drinkers by 23% (95% CI 0.64-0.93). However, when comparing those over (2 drinks/day) the recommendations to those within the recommendations (<2 drinks/day), there was a statistically significant association suggesting an increase in all-cause mortality (aHR 1.45, 95% CI (1.06-2.00)). However, alcohol consumption was statistically significantly or borderline related to an increased risk of prostate cancer-specific mortality. Specifically, for those above the CCS recommended levels (2 drinks/day) there was a 1.82 (95% CI 1.07-3.10) and 1.61 (95% CI 1.01-2.65) times increase in prostate cancer-specific mortality when compared to non-drinkers and those within the CCS recommendations (<2 drinks/day). These results were similar in the models not controlling for competing risks. First recurrence/progression or new primary cancer was not statistically significantly associated with increased alcohol intake although some suggestion of increased risks with higher levels of alcohol consumption were observed.
Different types of average alcohol consumption postdiagnosis (up to 3 years) are presented in Table 3 . While only speculative, the highest quartile of liquor consumption was statistically significantly associated with prostate cancerspecific mortality when compared to non-drinkers (aHR: 1.78, 95% CI: 1.17-2.70) and the lowest quartile of drinking (aHR: 2.20, 95% CI: 1.07-4.53) with evidence of a linear trend. These results were similar when not controlling for competing risks (aHR: 1.66, 95% CI: 1.09-2.53; aHR: 2.41, 95% CI: 1.20-4.84). Other types of alcohol, including beer and wine, were not consistently associated with all-cause mortality or prostate cancer-specific mortality.
When examining the change in alcohol consumption behavior from pre-diagnosis to post-diagnosis, the most common pattern observed was low pre-diagnosis drinking to no drinking/low drinking post-diagnosis (n 5 335 participants). The second most common pattern was observed in men who were consistently categorized in the highest levels both preand post-diagnosis (n 5 160). The remaining patterns of changes in alcohol consumption were high pre-diagnosis intake to no/low drinking post-diagnosis (n 5 149), no/low pre-diagnosis to high post-diagnosis drinking (n 5 120) and finally no pre-diagnosis drinking to no/low post-diagnosis drinking (n 5 65) (Supporting Information Table S1 ).
When these patterns were examined with respect to survival outcomes (Table 4) , those who consistently drank alcohol at the highest quartiles pre-and post-diagnosis were associated with a 2.67 increased risk (95% CI: 1.28-5.56) of prostate cancer-specific mortality as compared to those who did not drink or drank very little post-diagnosis. This association was observed regardless of controlling for competing risks or not. Elevated but non statistically significant associations were found for all-cause mortality and first recurrence/ progression or new primary cancer for this pattern of consistently high alcohol intake. Similarly, those who were in the highest quartile and those in the lower quartiles of alcohol consumption pre-diagnosis but who stopped drinking alcohol post-diagnosis were associated with a statistically significant increased risk for prostate cancer-specific mortality when controlling for competing risks (highest quartile: aHR 2.16, 95% CI 1.06-4.43; lower quartiles: aHR 2.12, 95% CI 1.08-4.16). These associations were found for first recurrence/progression or new primary cancer (highest quartile: aHR 1.72, 95% CI 1.05-2.80; lower quartiles: aHR 1.70, 95% CI 1.07-2.67), but not all-cause mortality.
Not adjusting for competing risks in the prostate cancerspecific mortality models attenuated the associations with alcohol consumption and therefore, Fine and Gray competing risk models are presented in all tables next to the Cox proportional hazards regression models. Furthermore, models are presented with a non-drinking referent group and the lowest quartile of drinking as the referent group. Removing participants diagnosed with stages T3/T4 prostate cancer Values are means 6 standard deviation or n (%).
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Farris et al. No drinking as reference group. 4 Lowest drinker group as reference group. Models are adjusted for: age at diagnosis, stage at diagnosis, prostatectomy, hormone therapy, radiation therapy, PSA levels at diagnosis, Charlson comorbidity score, Gleason score at diagnosis, smoking status at diagnosis, lifetime total physical activity (MET-hour-week/year), BMI at diagnosis, education level and how often (on average) participants went for a general check-up in their lifetime prior to diagnosis of prostate cancer. 1 Treating all events not prostate-cancer related as censored. 2 Competing risk Fine and Gray model; competing risk is death due to other causes, not specific to prostate cancer. 3 No drinking as reference group. 4 Lowest drinker group as reference group.
Farris et al.
slightly attenuated the main results (see Supporting Information Table S3 for details). However, excluding the first 2 years of participants follow-up time after prostate cancer diagnosis did not change the statistical significance of any results. The GBTM identified two groups with a quadratic functional form as the best fitting model (BIC 5 264,545.63). Most participants (95.9%; Group 1) fell into one cluster of alcohol consumption behavior while only a small percentage (4.1%; Group 2) were in the second group (Supporting Information Fig. S1 ). Group 1 has a relatively low level of alcohol intake over their lifetimes (<1,000 drinks pre-diagnosis) and consistent amount of alcohol with only slight curvature (linear slope: 35.78, p < 0.01; quadratic estimate: 20.46, p < 0.01) upwards between the ages of 20-50 years followed by a reduction with older age. However, Group 2 resulted in a drastic upwards trajectory (linear slope: 249.40, p < 0.01; quadratic estimate: 22.40; p < 0.01) up to 50 years of age (6,000 drinks), followed by a decrease.
Discussion
We were able to investigate how average alcohol consumption post-prostate cancer diagnosis (up to 3 years) related to survival after diagnosis. There was a statistically significant increased risk of mortality with increased alcohol consumption, particularly prostate cancer-specific mortality. This association was not as strong or consistent for all-cause mortality or first recurrence/progression or new primary cancer. When assessing the subgroup who consume alcohol (excluding nondrinkers), some associations were attenuated but for prostate cancer-specific mortality a statistically significant association remained. Although exploratory, our results also suggested that the statistically significant associations indicating an increased risk driven by liquor consumption, not beer or wine consumption. However, these results should be interpreted with caution due to the high proportion of non-drinkers in each alcohol type ranging from 43% to 45%. Furthermore, when evaluating associations between change from pre-to post-diagnosis alcohol consumption behaviors, consistently high (both pre-and post-diagnosis) consumption participants resulted in the highest risk of prostate cancer-specific mortality relative to non-drinkers. These differences between all-cause mortality and prostate cancer-specific mortality may be attributable to the possible protective associations that have been shown with occasional alcohol consumption in other health conditions such as cardiovascular disease. 25 Biological mechanisms that may explain how alcohol consumption is associated with prostate-cancer-specific mortality remain largely unknown and complex. Most proposed mechanisms in the literature to date focus on alcohol consumption and prostate cancer risk. For instance, it has been suggested that light-moderate alcohol consumption has been shown to act as an anti-inflammatory and anti-androgenic agent, whereas heavy alcohol consumption may act as an inflammatory agent, increase oxidative stress levels and alter hormone levels, thus increasing prostate cancer risk. [26] [27] [28] Furthermore, some reports have hypothesized that alcohol may act as a solvent for other carcinogens (i.e., tobacco) or potentially through genotoxic effects of the alcohol metabolite, acetaldehyde. 29 More generally, alcohol has been shown to affect DNA repair, metabolism of nutrients activation and clearance or carcinogens and direct effects on tissue and solubility of carcinogens. 30 However, for survival, literature regarding mechanisms underlying the role of alcohol is limited in both animals and humans. It is suggested that research focusing on activation of the immune system, strategies to improve effective immunotherapy and defining epigenetic mechanisms that modulate cancer progression would have great potential. 31 Previously, only a few studies have investigated the association between alcohol consumption and survival. [13] [14] [15] [16] One study 13 found a statistically significant decrease in prostate cancer mortality with high frequency alcohol consumers relative to non-drinkers. Interestingly, a 30-year prospective cohort study of Finnish twins 14 found statistically significant increased risk of mortality in non-drinkers when compared Table 4 . Change in dose of average alcohol consumption (drinks/week) between pre-diagnosis lifetime to post-diagnosis (up to 3 years) and mortality, first recurrence/progression or new primary cancer outcomes after a prostate cancer diagnosis in the Prostate Cancer Cohort Study, Alberta, Canada (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) to low drinkers. This study included 11,372 twins and had 110 prostate cancer deaths. The Asia Cohort Consortium did not find an association between alcohol consumption and prostate cancer mortality. Common to all studies was the potential for measurement error, since alcohol consumption was collected through self-reported questionnaires, whereas our study collected data through in-person interviews. Finally, another study 16 that did a Mendelian randomization examining alcohol metabolites and prostate progression observed statistically significant associations between increased alcohol intake and increased risk of progression. Overall, the literature regarding alcohol consumption and survival after prostate cancer is in its infancy and more studies are needed to fully substantiate alcohol's role in prostate cancer survival.
Limitations may have influenced our results and should be considered in future research. First, distinguishing those who do not drink alcohol by choice and those who have been diagnosed with a comorbidity that hinders their alcohol consumption is important. While we did adjust for postdiagnosis comorbidities, it would be interesting to capture reasons for not drinking in future research, especially since there appeared to be a difference between all-cause mortality and prostate cancer-specific mortality associations. Furthermore, conducting subgroup analyses on participants with and without comorbidities at prostate cancer diagnosis would be beneficial. Our study had 71 participants with no comorbidities, and therefore were underpowered for any subgroup testing by comorbidity status. On another note, despite conducting interview-administered data collection with cognitive methods to improve participant recall, our data on alcohol intake may be biased, because of social desirability. Some men may have underreported their alcohol consumption thereby causing a differential misclassification bias that may have overestimated our results. Since we did find statistically significant results, the impact of these biases would be influential and should be considered when interpreting our results. On the contrary, sicker patients may attribute their alcohol consumption with their prostate cancer diagnosis and over-report their alcohol consumption, also causing an overestimation. However, since the interviewers were formally trained in cognitive methods and were collecting a variety of lifestyles and behaviors in addition to our sensitivity analysis excluding stages T3/T4 prostate cancers, these scenarios of misclassification are minimized. In addition, we attempted to test multiple confounders and effect modifiers to reduce the risk of bias or misinterpretation of our results, however, future research in a larger sample may need to consider if different prognostic factors influence these relations since this was not our objective and we were underpowered to detect these potential differences. Furthermore, generalizability may be limited and our results only apply to those diagnosed with T2 (invasive) prostate cancer and for the post-diagnosis alcohol consumption survival models, only to those prostate cancer survivors who survived up to 3 years post-diagnosis.
Our study has several strengths that also need to be considered. First, it is one of the only studies to our knowledge to assess lifetime pre-diagnosis and post-diagnosis alcohol consumption and how post-diagnosis alcohol consumption is associated with all-cause mortality, prostate cancer-specific mortality and first recurrence/progression or new primary cancer outcomes. Furthermore, in our secondary objectives we attempted to identify different behavioral clusters in a prostate cancer population. Although we did not find multiple behavioral patterns, future research in a larger sample may be warranted to more fully elucidate lifetime patterns of alcohol drinking and their potential influences on mortality. Our study had a long follow-up period of 19 years, allowing us to examine the long-term associations of alcohol consumption on survival. Furthermore, we could compare competing risks (although Fine and Gray methods are not directly comparable to Cox proportional hazards [due to different risk set composition]) 32 in prostate cancer-specific mortality outcomes, which were in fact influencing the association between alcohol consumption and mortality related to prostate cancer. Alcohol consumption was associated with prostate cancer survival after diagnosis. The associations of post-diagnosis alcohol consumption were more consistently related to prostate cancer-specific mortality. Specifically, men who drink above the CCS recommendations were associated with the largest burden on prostate cancer-specific survival. Furthermore, consumption of alcohol in the highest quartile preand post-diagnosis was associated with the most increased risk, relative to non-drinkers. Secondarily, we did find a small group of men who followed an interesting trajectory of alcohol consumption through their life-course. Future research examining if subgroups within this population (e.g., stage of prostate cancer, older vs. younger, those with co-morbidities vs. not) are at a heightened risk for mortality is warranted.
